methotrexate has been researched along with Deafness, Transitory in 7 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (14.29) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 4 (57.14) | 24.3611 |
2020's | 2 (28.57) | 2.80 |
Authors | Studies |
---|---|
Cho, HH; Choi, Y; Lee, S; Umugire, A | 1 |
Clay, S; Doss, J; Fang, Z; Moore, B; Musso, A; Norman, M; Prasad, P; Sheets, G; Tsien, F; Umrigar, A | 1 |
Bagatell, R; Balamuth, N; Balis, F; Fox, E; Levin, K; Segers, B; Womer, R; Zhu, Y | 1 |
Bruneau, B; Chappé, C; Gandemer, V; Robert, G; Taque, S | 1 |
Ash, S; Cohen, IJ; Issakov, J; Kollender, Y; Shkalim-Zemer, V; Toledano, H; Yaniv, I | 1 |
Grier, HE; Janeway, KA | 1 |
Benesch, M; Kerbl, R; Lackner, H; Oberbauer, R; Pakisch, B; Schwinger, W; Urban, C | 1 |
1 review(s) available for methotrexate and Deafness, Transitory
Article | Year |
---|---|
Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects.
Topics: Antidotes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Doxorubicin; Hearing Loss; Heart Diseases; Humans; Ifosfamide; Infertility; Kidney Diseases; Methotrexate; Neoplasms, Second Primary; Neurotoxicity Syndromes; Osteosarcoma; Survivors | 2010 |
2 trial(s) available for methotrexate and Deafness, Transitory
Article | Year |
---|---|
Pantoprazole, an Inhibitor of the Organic Cation Transporter 2, Does Not Ameliorate Cisplatin-Related Ototoxicity or Nephrotoxicity in Children and Adolescents with Newly Diagnosed Osteosarcoma Treated with Methotrexate, Doxorubicin, and Cisplatin.
Topics: Acute Kidney Injury; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; Cisplatin; Cross-Over Studies; Doxorubicin; Female; Hearing; Hearing Loss; Humans; Kidney; Male; Methotrexate; Organic Cation Transporter 2; Osteosarcoma; Pantoprazole; Young Adult | 2018 |
Synchronous radiochemotherapy in unfavorable brain tumors of children and young adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Chemical and Drug Induced Liver Injury; Chemotherapy, Adjuvant; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Deafness; Disease Progression; Disease-Free Survival; Etoposide; Follow-Up Studies; Glioma; Hearing Loss; Hematologic Diseases; Humans; Ifosfamide; Infections; Life Tables; Lomustine; Medulloblastoma; Methotrexate; Prognosis; Radiotherapy, Adjuvant; Remission Induction; Vincristine | 1998 |
4 other study(ies) available for methotrexate and Deafness, Transitory
Article | Year |
---|---|
Efficiency of antioxidant Avenanthramide-C on high-dose methotrexate-induced ototoxicity in mice.
Topics: Animals; Antioxidants; Apoptosis; Cell Line; Cisplatin; Hearing Loss; Methotrexate; Mice; ortho-Aminobenzoates; Ototoxicity; Reactive Oxygen Species | 2022 |
Is Methotrexate Ototoxic? Investigating the Ototoxic Late Effects of Pediatric Cancer Treatment.
Topics: Antineoplastic Agents; Child; Cisplatin; Deafness; Hearing Loss; Humans; Methotrexate; Neoplasms; Ototoxicity; Retrospective Studies | 2023 |
Hearing loss during osteosarcoma chemotherapy: when acute ifosfamide toxicity revealed unnoticed methotrexate encephalopathy.
Topics: Adolescent; Antineoplastic Agents; Bone Neoplasms; Brain; Brain Diseases; Female; Hearing Loss; Humans; Ifosfamide; Magnetic Resonance Imaging; Methotrexate; Osteosarcoma | 2014 |
Highly effective reduced toxicity dose-intensive pilot protocol for non-metastatic limb osteogenic sarcoma (SCOS 89).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Doxorubicin; Drug Substitution; Etoposide; Female; Follow-Up Studies; Hearing Loss; Humans; Ifosfamide; Kidney Diseases; Leucovorin; Male; Methotrexate; Osteosarcoma; Pilot Projects; Stroke Volume; Survival Rate; Treatment Outcome; Young Adult | 2015 |